Latest News

MMS Promotes Two Leaders at its Asia Headquarters amid Strong Growth Period

Is among the lowest attrition rates in the pharmaceutical industry regionally

Bangalore, India (June 7, 2018) – MMS Holdings Inc. (MMS) – a global, leading clinical research organization – announced today two major promotions at its Asia headquarters, including Dr. Arunima Sen has been promoted to the position of Head, Drug Safety and Medical Writing in India, and Nandini Vijaisimha has been promoted to the position of Head, HR and Administration in India.

The promotions allow for these leaders who have been with the organization for a decade to lead alongside global counterparts and exemplify the “One MMS” philosophy. Further, in a highly competitive industry, it sets MMS apart with unique talent and low attrition rates that far out-pace the industry average. It is estimated that attrition rates in the Indian pharmaceutical sector are suffering at 30-35 percent annually, according to Business Standard. MMS is currently below six percent annually in the region and has always remained at or below this mark.

“The dedication of our experts internally, notably Ms. Vijaisimha and Dr. Sen, is unwavering,” said Michelle Gayari, Executive Director, Global Operations, MMS, based at the company’s Canton, Mich. headquarters. “For nearly a decade, both our staff and our customers have come to rely on these leaders. In India, our integral team is not just an extra pair of hands as in some companies; they are collaborative scientists and researchers that have assisted in building strong teams and cultivated these strengths with a quality-focused, and a client-centric, mindset.”

Growth in Asia has kept pace with the company’s U.S. headquarters at double digit movement annually since inception.

“I have been focused on building a team with solid technical and scientific skillsets, but beyond that, those who will operate globally, while bringing creative solutions and efficiencies to daily work. I am proud to have these efforts recognized by the organization,” said Dr. Sen.
“Every day, I focus on helping motivate, mentor, and train colleagues to be their best, showing them that MMS is truly one of the best companies to work for. I am honored and humbled by this recognition,” said Vijaisimha.

MMS recently strengthened its position in Asia with the opening of its Hyderabad office in 2016. For more information, follow MMS on LinkedIn.

About MMS
MMS is a global, leading clinical research organization that supports the pharmaceutical and biotech industries with a proven, scientific approach to complex regulatory submission challenges. As a data CRO, we are pioneers and leaders in regulatory submissions for our sponsors. Strong industry experience and a data-driven approach to drug development make MMS a valuable partner in creating compelling submissions that meet rigorous regulatory standards. For more information, visit www.mmsholdings.com.

Media Contact
Prasad Babu
media@mmsholdings.com

Suggested For You

news

November 19th, 2024

MMS Recognized as a Top Workplace by Detroit Free Press and USA Today Network for the Fourth Consecutive Year

news

November 8th, 2024

MMS Named a Finalist in the 2024 Fierce CRO Awards for Leadership in Regulatory Compliance

news

October 15th, 2024

MMS Recognized with EcoVadis Bronze Medal for Leadership in ESG Sustainability Efforts as a Leading Clinical Research Organization (CRO)

news

July 17th, 2024

Industry Veteran Ben Dudley Joins MMS as Chief Commercial Officer (CCO) to Drive Continued Growth for the Data-focused Clinical Research Organization

news

April 4th, 2024

MMS Hires Pharmaceutical Industry Veteran James Zee for Global Biometrics Leadership in Europe Amid Strong Regional Growth

news

March 6th, 2024

MMS Holdings Inc – A Data-Centric CRO Powerhouse Reshaping Drug Development on a Global Scale

news

December 13th, 2023

MMS Supported Lykos Therapeutics: NDA Submitted to FDA for First Psychedelic-Assisted Therapy for PTSD

news

April 18th, 2023

MMS Named Great Place to Work in the UK as Growth in the Region Doubles

news

March 21st, 2023

MMS Scientific Advisory Board’s New Members Expand CRO’s Therapeutic Expertise

news

February 21st, 2023

MMS Partners with I-ACT to Advance Children’s Clinical Trials

news

February 7th, 2023

Award-Winning Data CRO Expands Executive Leadership to Support Company’s Next Stage of Growth

news

January 11th, 2023

MMS Named a Great Place to Work in India